X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1357) 1357
Publication (74) 74
Book Review (39) 39
Newsletter (6) 6
Book Chapter (4) 4
Conference Proceeding (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
exenatide (970) 970
index medicus (893) 893
humans (892) 892
diabetes mellitus, type 2 - drug therapy (708) 708
type 2 diabetes (700) 700
endocrinology & metabolism (564) 564
hypoglycemic agents - therapeutic use (511) 511
diabetes (497) 497
male (486) 486
glucagon-like peptide-1 (450) 450
glycemic control (450) 450
liraglutide (424) 424
female (404) 404
insulin (333) 333
middle aged (328) 328
glucose (319) 319
peptides - therapeutic use (303) 303
hypoglycemic agents - administration & dosage (301) 301
animals (287) 287
metformin (287) 287
pharmacology & pharmacy (280) 280
venoms - therapeutic use (271) 271
open-label (269) 269
diabetes mellitus, type 2 - blood (250) 250
glucagon (248) 248
hypoglycemic agents - adverse effects (238) 238
treatment outcome (230) 230
hypoglycemic agents (219) 219
peptides - administration & dosage (217) 217
glucagon-like peptide 1 - analogs & derivatives (213) 213
peptides (211) 211
diabetes therapy (209) 209
drug therapy (206) 206
glp-1 (205) 205
aged (203) 203
internal medicine (203) 203
double-blind (194) 194
venoms - administration & dosage (194) 194
adult (193) 193
blood glucose - metabolism (189) 189
analysis (187) 187
care and treatment (185) 185
exenatide exendin-4 (185) 185
safety (184) 184
diabetes mellitus (183) 183
blood glucose - drug effects (177) 177
glucagon-like peptide 1 - therapeutic use (171) 171
hypoglycemic agents - pharmacology (171) 171
treated patients (170) 170
exendin-4 (167) 167
glucagon-like peptide-1 receptor (167) 167
efficacy (166) 166
research (164) 164
peptides - pharmacology (151) 151
beta-cell function (150) 150
drug administration schedule (149) 149
medicine, general & internal (149) 149
peptides - adverse effects (149) 149
dextrose (148) 148
type 2 diabetes mellitus (147) 147
glycated hemoglobin a - metabolism (146) 146
obesity (141) 141
drug therapy, combination (140) 140
venoms - pharmacology (138) 138
receptors, glucagon - agonists (137) 137
clinical trials (136) 136
insulin glargine (136) 136
sitagliptin (136) 136
type-2 diabetes-mellitus (135) 135
medicine & public health (134) 134
diabetes mellitus, type 2 - metabolism (132) 132
venoms - adverse effects (129) 129
body weight (122) 122
risk factors (122) 122
hypoglycemia (121) 121
hyperglycemia (116) 116
glycosylated hemoglobin (115) 115
incretins - therapeutic use (111) 111
glucagon-like peptide-1 receptor - agonists (105) 105
metformin-treated patients (103) 103
health aspects (101) 101
insulin - therapeutic use (100) 100
dosage and administration (99) 99
insulin resistance (98) 98
metformin - therapeutic use (98) 98
glucagon-like peptide 1 (95) 95
insulin - metabolism (94) 94
twice-daily exenatide (94) 94
diabetes mellitus, type 2 - complications (93) 93
sulfonylurea (93) 93
therapy (93) 93
mellitus (92) 92
rats (91) 91
endocrinology (90) 90
weight (89) 89
medicine, research & experimental (88) 88
basal insulin (87) 87
blood sugar (87) 87
dipeptidyl peptidase-4 inhibitor (85) 85
mice (85) 85
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetologia, ISSN 0012-186X, 2/2007, Volume 50, Issue 2, pp. 259 - 267
Journal Article
Journal Article
Journal Article
Journal of Diabetes Investigation, ISSN 2040-1116, 01/2013, Volume 4, Issue 1, pp. 53 - 61
Aims/Introduction To compare safety and efficacy of the extended‐release formulation exenatide once weekly (EQW) vs exenatide twice daily (EBID) for 26 weeks... 
Type 2 diabetes | Asian | Exenatide | GLYCEMIC CONTROL | RANDOMIZED-TRIAL | OPEN-LABEL | TREATED PATIENTS | INSULIN SENSITIVITY | BETA-CELL FUNCTION | CROSS-SECTIONAL SURVEY | ENDOCRINOLOGY & METABOLISM | BODY-MASS INDEX | JAPANESE PATIENTS | BLOOD-GLUCOSE CONTROL | Glycosylated hemoglobin | Hypoglycemic agents | Blood sugar | Confidence intervals | Weight control | Glucose | Diabetes | Original
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1688 - 1697
Aims To estimate the long‐term cost‐effectiveness of exenatide twice daily vs insulin glargine once daily as add‐on therapy to oral antidiabetic agents (OADs)... 
pharmaco‐economics | antidiabetic drug | cost‐effectiveness | type 2 diabetes | insulin therapy | exenatide | cost-effectiveness | pharmaco-economics | METFORMIN | RISK-FACTORS | CARDIOVASCULAR OUTCOMES | RETROSPECTIVE COHORT | MELLITUS | MODEL | ADHERENCE | ENDOCRINOLOGY & METABOLISM | LIFETIME HEALTH OUTCOMES | WEIGHT-GAIN | UTILITY | Hypoglycemia - epidemiology | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diabetic Cardiomyopathies - economics | Models, Economic | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Diabetic Angiopathies - prevention & control | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Diabetic Angiopathies - economics | Direct Service Costs | Administration, Oral | Venoms - adverse effects | Hyperglycemia - economics | Drug Therapy, Combination - economics | Diabetic Angiopathies - therapy | Diabetic Cardiomyopathies - epidemiology | Venoms - therapeutic use | Quality of Life | Hyperglycemia - epidemiology | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Cardiovascular Diseases - therapy | Diabetes Mellitus, Type 2 - economics | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Peptides - economics | Venoms - administration & dosage | Diabetic Cardiomyopathies - prevention & control | Diabetic Cardiomyopathies - therapy | Hypoglycemia - economics | Diabetes Mellitus, Type 2 - complications | Cardiovascular Diseases - economics | Insulin Glargine - adverse effects | Drug Administration Schedule | Venoms - economics | Insulin Glargine - economics | Insulin Glargine - therapeutic use | China - epidemiology | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Cost-Benefit Analysis | Incretins - adverse effects | Diabetic Angiopathies - epidemiology | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hyperglycemia - therapy | Peptides - adverse effects | Peptides - therapeutic use | Incretins - economics | Type 2 diabetes | Insulin | Analysis | Diabetes therapy | Literature reviews | Databases | Diabetes mellitus | Clinical trials | Diabetes | Cost analysis | Hypoglycemia | Patients | Diabetes mellitus (non-insulin dependent)
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1793 - 1797
The range of glycated haemoglobin (HbA1c) responses and characteristics associated with above‐average response to exenatide twice daily and once weekly were... 
predictors | exenatide twice daily | glucagon‐like peptide‐1 receptor agonist | exenatide once weekly | glucagon-like peptide-1 receptor agonist | INSULIN |